Antibody subclass profile against Leishmania braziliensis and Leishmania amazonensis in the diagnosis and follow-up of mucosal leishmaniasis

被引:23
作者
Pedras, MJ
Orsini, M
Castro, M
Passos, VMA
Rabello, A [1 ]
机构
[1] Fundacao Oswaldo Cruz, Lab Clin Res, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil
[2] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil
[3] Santa Casa Belo Horizonte, Belo Horizonte, MG, Brazil
[4] Fundacao Oswaldo Cruz, Lab Epidemiol, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil
关键词
D O I
10.1016/S0732-8893(03)00141-X
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Sensitivities and specificities of IgG subclasses-ELISA and IgG-indirect fluorescent antibody test (IFAT) against Leishmania braziliensis (Lb) and L. amazonensis (La) antigens were determined in 17 patients with mucosal (ML) and 19 with muco-cutaneous (MCL) leishmaniasis. Using IFAT-IgG both antigens gave high sensitivities and were statistically similar, being 89.5% with La and 100% with Lb. Using ELISA, the highest sensitivity was achieved with total IgG for ML (94.7% with both antigens) and MCL (100% with both antigens). Cross-reactivity, observed with Chagas disease and malaria sera reduced the specificity of the IgG-based assays, being 50 to 70% with IFAT and 40 to 70% with ELISA. An increase in specificity was obtained with IgG1-ELISA (90% with Lb and 100% with La). Serum levels of anti-Lb-IgG and IgG3 dropped 90 days after treatment. IgG subclasses antibody detection constitute an valuable alternative to increase the efficiency of sorological diagnostics of ML/MCL. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:477 / 485
页数:9
相关论文
共 29 条
[1]  
BHATTACHARYYA G, 1977, STAT CONCEPTS METHOD, P460
[2]   IGG ANTIBODY REACTIVITY WITH TRYPANOSOMA-CRUZI AND LEISHMANIA ANTIGENS IN SERA OF PATIENTS WITH CHAGAS-DISEASE AND LEISHMANIASIS [J].
CHILLER, TM ;
SAMUDIO, MA ;
ZOULEK, G .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1990, 43 (06) :650-656
[3]  
Cuba Cuba C.A., 1981, Bulletin of the Pan American Health Organization, V15, P249
[4]  
da Matta VLR, 2000, J CLIN LAB ANAL, V14, P5, DOI 10.1002/(SICI)1098-2825(2000)14:1&lt
[5]  
5::AID-JCLA2&gt
[6]  
3.0.CO
[7]  
2-F
[8]  
ELAMIN EM, 1986, CLIN EXP IMMUNOL, V64, P14
[9]  
ELASSAD AMS, 1994, CLIN EXP IMMUNOL, V95, P294, DOI 10.1111/j.1365-2249.1994.tb06526.x
[10]   Leishmaniasis [J].
Grevelink, SA ;
Lerner, EA .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 34 (02) :257-272